New HIV drug combo shows promise for transplant patients
NCT ID NCT03360682
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 25 times
Summary
This study looked at a new HIV medication combination (dolutegravir plus two NRTIs) in 19 people with HIV who had received a solid organ transplant (kidney, liver, or heart). The goal was to see if the HIV drug interacts safely with the anti-rejection medicines they must take for life. Researchers measured drug levels in the blood and checked for side effects and viral control. The study was completed and provides important safety data for this group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hospital Clínic de Barcelona
Barcelona, 08036, Spain
Conditions
Explore the condition pages connected to this study.